Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Pharmacokinetics of NNC0560-0004 in Healthy Volunteers
NCT06133270Phase 1Completed
- Sponsor
- Novo Nordisk
- Start
- Nov 2023
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in metabolic dysfunction-associated steatohepatitis (MASH) comparing NNC0560-0004 with Placebo (2 arms). Primary endpoints: Treatment-emergent adverse events (Part A), Treatment-emergent adverse events (Part B) and 1 more. Started Nov 2023; status: completed.
02
Drugs
NNC0560-0004
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)
Beyond the preview
Go deeper on NCT06133270.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06133270.